APA 6th Edition Kaštelan, D. (2007). Osteoporoza u muškaraca. Arhiv za higijenu rada i toksikologiju, 58 (1), 25-32. Preuzeto s https://hrcak.srce.hr/10612
MLA 8th Edition Kaštelan, Darko. "Osteoporoza u muškaraca." Arhiv za higijenu rada i toksikologiju, vol. 58, br. 1, 2007, str. 25-32. https://hrcak.srce.hr/10612. Citirano 27.09.2020.
Chicago 17th Edition Kaštelan, Darko. "Osteoporoza u muškaraca." Arhiv za higijenu rada i toksikologiju 58, br. 1 (2007): 25-32. https://hrcak.srce.hr/10612
Harvard Kaštelan, D. (2007). 'Osteoporoza u muškaraca', Arhiv za higijenu rada i toksikologiju, 58(1), str. 25-32. Preuzeto s: https://hrcak.srce.hr/10612 (Datum pristupa: 27.09.2020.)
Vancouver Kaštelan D. Osteoporoza u muškaraca. Arh Hig Rada Toksikol. [Internet]. 2007 [pristupljeno 27.09.2020.];58(1):25-32. Dostupno na: https://hrcak.srce.hr/10612
IEEE D. Kaštelan, "Osteoporoza u muškaraca", Arhiv za higijenu rada i toksikologiju, vol.58, br. 1, str. 25-32, 2007. [Online]. Dostupno na: https://hrcak.srce.hr/10612. [Citirano: 27.09.2020.]
Sažetak With the prolongation of life expectancy, osteoporosis has become an increasing problem in the majority of developed countries worldwide. The paper discusses the frequency, pathogenesis, diagnostic criteria and treatment options for osteoporosis in men. Every third hip fracture occurs in men, and more than 11 % of the male population over the age of 50 years suffer the fracture. Diagnostic tests for idiopathic osteoporosis are performed in men under 60 years of age without other potential risk factors of developing the disease. In the majority of cases, their low bone mineral density (BMD) is caused by a low peak bone mass. Secondary osteoporosis occurs in about 30 % of men, and involutionary osteoporosis developed in men over 60 years of age results from their decreased testosterone and IGF-1 levels. The study results showing that BMD levels in both sexes provide similar fracture risk information suggest that the existing diagnostic criteria for female osteoporosis can also be employed in men. It has been proved that biphosphonate and teriparitide therapy significantly increase BMD levels in men. The administration of androgens has been shown to be effective in men with hypogonadism, although their validity for patients with eugonadism has not yet been discussed. An improved knowledge of the bone metabolism and bone remodelling has recently opened the door to an extensive series of molecules that may play a key role in the treatment of male osteoporosis in the future.